- Home
- NVNO vs LUCD Comparison
NVNO vs LUCD Comparison
Compare NVNO & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- LUCD
- Stock Information
- Founded
- NVNO 1987
- LUCD 2018
- Country
- NVNO United States
- LUCD United States
- Employees
- NVNO N/A
- LUCD N/A
- Industry
- NVNO Medical/Dental Instruments
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NVNO Health Care
- LUCD Health Care
- Exchange
- NVNO Nasdaq
- LUCD Nasdaq
- Market Cap
- NVNO 58.9M
- LUCD 51.6M
- IPO Year
- NVNO N/A
- LUCD 2021
- Fundamental
- Price
- NVNO $3.15
- LUCD $0.90
- Analyst Decision
- NVNO
- LUCD Strong Buy
- Analyst Count
- NVNO 0
- LUCD 4
- Target Price
- NVNO N/A
- LUCD $3.63
- AVG Volume (30 Days)
- NVNO 147.8K
- LUCD 227.6K
- Earning Date
- NVNO 02-27-2025
- LUCD 03-24-2025
- Dividend Yield
- NVNO N/A
- LUCD N/A
- EPS Growth
- NVNO N/A
- LUCD N/A
- EPS
- NVNO N/A
- LUCD N/A
- Revenue
- NVNO N/A
- LUCD $4,189,000.00
- Revenue This Year
- NVNO N/A
- LUCD $91.72
- Revenue Next Year
- NVNO N/A
- LUCD $139.38
- P/E Ratio
- NVNO N/A
- LUCD N/A
- Revenue Growth
- NVNO N/A
- LUCD 179.27
- 52 Week Low
- NVNO $2.45
- LUCD $0.63
- 52 Week High
- NVNO $6.97
- LUCD $1.50
- Technical
- Relative Strength Index (RSI)
- NVNO 46.80
- LUCD 59.89
- Support Level
- NVNO $3.13
- LUCD $0.81
- Resistance Level
- NVNO $3.68
- LUCD $0.90
- Average True Range (ATR)
- NVNO 0.21
- LUCD 0.04
- MACD
- NVNO -0.01
- LUCD 0.01
- Stochastic Oscillator
- NVNO 8.20
- LUCD 86.87
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.